Core Viewpoint - The stock of Insilico Medicine (03696) rose over 10% following the announcement of a milestone payment from Menarini Group after the completion of the first patient dosing in the Phase I clinical trial of MEN2501, a KIF18A inhibitor designed for treating chromosomal instability solid tumors [1] Group 1: Company Developments - Insilico Medicine received a milestone payment of HKD 39 million from Menarini Group after the first patient dosing in the MEN2501 project [1] - This follows a previous milestone payment of over HKD 23.4 million received in July 2025 for development and regulatory milestones [1] - MEN2501 is a highly differentiated KIF18A inhibitor designed using Insilico's generative AI engine [1] Group 2: Industry Insights - Morgan Stanley's report highlights Insilico Medicine as a leader in the AIDD (AI-Driven Drug Discovery) field, noting substantial progress in both technology validation and application [1] - The execution capability of its chemical models supports a repeatable "1-to-N" innovation creation engine [1] - As biological model human validation becomes more evident, the potential upside for the company is expected to be further released as the industry enters a broader adoption phase of AIDD [1]
港股异动 | 英矽智能(03696)午后涨超10% MEN2501再获里程碑付款 大摩看好公司在AIDD领先地位